Rheumatoid arthritis

bDMARD refractory disease is a pain point in RA

Biologic refractory disease affects about 6% of patients with rheumatoid arthritis – with patients increasingly cycling through the available biologic disease-modifying antirheumatic drugs (bDMARDs). Defining refractory disease from when patients commenced on a third class of bDMARD, the UK biologics registry study found 6% of 13,502 patients were refractory over 111,034 patient years of follow-up. ...

Already a member?

Login to keep reading.

© 2021 the limbic